Akebia Therapeutics, Inc. AKBA
Akebia Therapeutics, Inc. (Nasdaq: AKBA) is a cardio-renal-metabolic drug developer. Its lead program, Vafseo (vadadustat), is in Phase 2 for anemia due to chronic kidney disease in adult patients on dialysis. Its next catalyst on record is Vafseo: TDAPA period transition to post-TDAPA period (2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Vafseo — TDAPA period transition to post-TDAPA period (2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Vafseo (vadadustat) | anemia due to CKD in adult patients on dialysis | small molecule | Approved |
| Auryxia (ferric citrate) | control of serum phosphorus in DD-CKD; treatment of IDA in NDD-CKD | small molecule | Approved |
| praliciguat | biopsy-confirmed focal segmental glomerulosclerosis (FSGS) | small molecule | Phase 2 |
| ebribafusp (ADX-097 / AKB-097) | IgA Nephropathy, C3 Glomerulopathy, Lupus Nephritis | protein/peptide | Phase 2 |
| AKB-9090 | cardiac surgery-related acute kidney injury (CS-AKI) | small molecule | Phase 1 |
| AKB-10108 | retinopathy of prematurity (ROP) in neonates | small molecule | Pre-clinical |
Recent results and decisions
- Nov 5, 2026met Akebia announced topline results of VOCAL trial showing vadadustat met the primary endpoint of non-inferiority to ESA based on change in hemoglobin.
VOCAL met the primary endpoint of non-inferiority to ESA based on change in hemoglobin.
Filing - Oct 31, 2026positive VOICE trial data presented at ASN Kidney Week demonstrated statistically significant improved safety outcomes for patients treated with vadadustat versus ESA.
The data demonstrated a statistically significant improved safety outcome in patients treated with vadadustat versus ESA on the hierarchical composite endpoint of all-cause mortality and hospitalization, driven by a significant reduction in hospitalization rate.
Filing - Sep 30, 2026started Akebia dosed the first patient in a Phase 2 open-label basket trial of ebribafusp alfa in multiple rare kidney diseases.
In September, Akebia announced it had dosed the first patient in a Phase 2 open-label basket trial of ebribafusp alfa, which Akebia believes has the potential to be a next-generation complement inhibitor.
Filing
1 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.